Featured Research

from universities, journals, and other organizations

Insights Into Anemia Control In Dialysis Patients

Date:
July 16, 2007
Source:
American Society of Nephrology
Summary:
Anemia is one of the most frequent complications of hemodialysis, and its correction is an important factor in restoring a tolerable quality of life to dialysis-dependent patients. Treatment with drugs called erythropoiesis-stimulating agents (ESAs), which stimulate the bone marrow to produce red blood cells, have been a major advance in the treatment of the anemia (low levels of red blood cells or hemoglobin, which carries oxygen in the blood) in chronic kidney disease (CKD).

Anemia is one of the most frequent complications of hemodialysis, and its correction is an important factor in restoring a tolerable quality of life to dialysis-dependent patients. Treatment with drugs called erythropoiesis-stimulating agents (ESAs), which stimulate the bone marrow to produce red blood cells, have been a major advance in the treatment of the anemia (low levels of red blood cells or hemoglobin, which carries oxygen in the blood) in chronic kidney disease (CKD). However, there is ongoing controversy related to the appropriate clinical use and high costs of ESAs.

An August study in Journal of the American Society of Nephrology (JASN) presents a detailed analysis of patterns of change in hemoglobin levels, lending new insights into the factors that control hemoglobin levels and variations in patient responses to ESAs. "Our paper provides one means of describing variations in hemoglobin levels among dialysis patients and opens up the possibility of optimizing the treatment system on a rational basis," according to Dr. Eric J. Will of St. James's University Hospital, Leeds, United Kingdom.

Based upon data from a recent clinical trial involving ESAs, Dr. Will and colleagues used an approach called functional data analysis to study changes in hemoglobin levels over time, including responses to ESA treatment. "Our technique allowed characterization of the variation of hemoglobin level and ESA doses through representation as waveforms," says Dr. Will. "Unlike most statistical methods, our method relied on few assumptions about their potential patterns."

The results suggested that hemoglobin levels were affected by the negative feedback control systems being attempted in clinical management. "This system can be conceived as an oscillation, like a pendulum, with the hemoglobin value swinging up and down over time," Dr. Will explains. "While these periodic effects may be seen as undesirable in clinical circumstances, they will be susceptible to manipulation and improvement only by acknowledging their true origins and designing experimental conditions that may lead to a means to improve matters."

The analysis also suggested that individual patients varied in their sensitivity to ESA treatment. The two different ESAs (epoetin beta and darbepoetin) compared in the original study produced a similar range of responses.

Dialysis patients receiving ESAs to treat anemia of kidney disease often have variations in hemoglobin levels. "These variations occur across the dialysis procedure and when patients become ill with other conditions, for whatever reason," Dr. Will explains. "There is also some wave-like variation over longer periods of time, perhaps across 20% of the range of an individual's hemoglobin values. This is likely to be caused by variations in the patients' response to dose changes of the ESAs, which are difficult to adjust perfectly to correct hemoglobin values to the desired range."

The results are especially timely because of two ongoing debates over the use of ESAs to control anemia in CKD. "One is an unresolved scientific controversy over the possible cardiovascular risk of treatment intended to produce higher (more normal) hemoglobin levels, and the use of generous doses of ESAs, in patients with kidney disease," Dr. Will explains. (A separate debate concerns the use of ESAs in cancer patients.)

"There is also apparently an economic dimension being played out in the health care system between the government and dialysis providers, relating to the necessary/desirable hemoglobin outcomes in kidney patients, the ESA doses being deployed, and the consequent costs." Dr. Will concludes, "Any possibility of reducing the variation in hemoglobin values and/or stabilizing the dose regimens is a contribution to both of these issues."

The study entitled, "Functional Data Analysis in Renal Anemia" will be available online at http://www.asn-online.org under Media, 2007, beginning on Wednesday, July 11 and in print in the August issue of the Journal of the American Society of Nephrology (JASN).


Story Source:

The above story is based on materials provided by American Society of Nephrology. Note: Materials may be edited for content and length.


Cite This Page:

American Society of Nephrology. "Insights Into Anemia Control In Dialysis Patients." ScienceDaily. ScienceDaily, 16 July 2007. <www.sciencedaily.com/releases/2007/07/070711135511.htm>.
American Society of Nephrology. (2007, July 16). Insights Into Anemia Control In Dialysis Patients. ScienceDaily. Retrieved September 17, 2014 from www.sciencedaily.com/releases/2007/07/070711135511.htm
American Society of Nephrology. "Insights Into Anemia Control In Dialysis Patients." ScienceDaily. www.sciencedaily.com/releases/2007/07/070711135511.htm (accessed September 17, 2014).

Share This



More Health & Medicine News

Wednesday, September 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Artificial Sweetener Could Promote Diabetes

Artificial Sweetener Could Promote Diabetes

Newsy (Sep. 17, 2014) Doctors once thought artificial sweeteners lacked the health risks of sugar, but a new study says they can impact blood sugar levels the same way. Video provided by Newsy
Powered by NewsLook.com
Ebola Vaccine Trial Gets Underway at Oxford University

Ebola Vaccine Trial Gets Underway at Oxford University

AFP (Sep. 17, 2014) A healthy British volunteer is to become the first person to receive a new vaccine for the Ebola virus after US President Barack Obama called for action against the epidemic and warned it was "spiralling out of control." Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Obesity Rates Steady Even As Americans' Waistlines Expand

Obesity Rates Steady Even As Americans' Waistlines Expand

Newsy (Sep. 17, 2014) Researchers are puzzled as to why obesity rates remain relatively stable as average waistlines continue to expand. Video provided by Newsy
Powered by NewsLook.com
President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins